Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - coffeinum; acidum acetylsalicylicum - freyðitafla - 500/50 mg

Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - acidum acetylsalicylicum; coffeinum - freyðitafla - 500 mg/50 mg

Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - betamethasonum díprópíónat; calcipotriolum inn - smyrsli - 50 míkrog/g + 0,5 mg/g

Unió Europea - islandès - EMA (European Medicines Agency)

nordic group b.v. - stendur - arthritis, psoriatic; psoriasis; arthritis, juvenile rheumatoid; arthritis, rheumatoid - Æxlishemjandi lyf - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.

Unió Europea - islandès - EMA (European Medicines Agency)

gilead sciences ireland uc - cobicistat - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.

Unió Europea - islandès - EMA (European Medicines Agency)

sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - blóðþurrðandi lyf - bráðri kransæðastíflu syndromemyocardial hjartaáfall.

Unió Europea - islandès - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - blóðþurrðandi lyf - duoplavin er ætlað til að koma í veg fyrir beinþrýstingslækkandi aukaverkanir hjá fullorðnum sjúklingum sem taka bæði klópídógrel og asetýlsalisýlsýru (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. nánari upplýsingar er að vísa til kafla 5.

Unió Europea - islandès - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - atosiban (as acetate) - Ótímabært fæðing - Önnur gynecologicals - atosiban er ætlað að tefja yfirvofandi fyrir tíma fæðingu í barnshafandi fullorðinn konur með:venjulegur legi samdrættir af minnsta kosti 30 sekúndur' lengd á hraða sem stóð 4 á 30 mínútur, legháls útvíkkun 1 til 3 cm (0-3 fyrir nulliparas) og effacement af stóð 50%;meðgöngu úr 24 fyrr en 33 lokið vikur;eðlilegt hjartsiátturinn.

Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - pimecrolimusum inn - krem - 1 %

Unió Europea - islandès - EMA (European Medicines Agency)

astellas pharma europe bv - takrólímus - graft rejection - Ónæmisbælandi lyf - fyrirbyggja grætt höfnun í fullorðinn nýra eða lifur ígrædd nýru viðtakendur. meðferð við höfnun á fjölgildingu sem er ónæm fyrir meðferð með öðrum ónæmisbælandi lyfjum hjá fullorðnum sjúklingum.